A protocol for the retina surgeon's safe initial intravitreal injections.
A protocol for the retina surgeon's safe initial intravitreal injections.
复制标题
DOI：
10.2147/opth.s12846
复制
发表时间：
2010-11-10
期刊：
影响因子：
--
通讯作者：
Reyes A
中科院分区：
文献类型：
--
作者：
Frenkel RE;Haji SA;La M;Frenkel MP;Reyes A
旨在确定外科医生使用特定方案进行初始连续玻璃体内注射的安全性，并审查可能归因于注射程序的并发症。回顾性病历审查。59名患者（30名女性，29名男性）接受玻璃体内注射哌加他尼、贝伐单抗或雷珠单抗作为新生血管性年龄相关性黄斑变性治疗的一部分。患者平均年龄为80岁。22例患者被诊断为或疑似患有青光眼。每位患者平均接受5.8次注射。共接受345次玻璃体内注射（104次哌加他尼，74次贝伐单抗，167次雷珠单抗）的59例患者的病历进行了审查。所有注射均在办公室环境中进行。使用聚维酮碘、局部抗生素和开睑器作为注射前程序的一部分。每次注射后立即评价视力和眼内压。注射后并发症的发生率，包括但不限于眼内炎、视网膜脱离、外伤性白内障和玻璃体出血。无眼内炎、毒性反应、外伤性白内障、视网膜脱离或玻璃体出血病例。眼睑肿胀、一过性飞蚊症、视网膜色素上皮撕裂、角膜水肿和角膜擦伤各1例。注射哌加他尼后有5例一过性无光感。玻璃体内注射严重并发症的发生率非常低。外科医生的初始玻璃体内注射可以使用该方案以非常高的安全度进行。
To determine the safety of a surgeon’s initial consecutive intravitreal injections using a specific protocol and to review the complications that may be attributed to the injection procedure. A retrospective chart review. Fifty-nine patients (30 females, 29 males) received intravitreal injections of pegaptanib, bevacizumab, or ranibizumab as part of their treatment for neovascular age-related macular degeneration. The average patient age was 80 years. Twenty-two patients were diagnosed with or suspected of having glaucoma. Each patient received an average of 5.8 injections. The charts of 59 patients who received a total of 345 intravitreal injections (104 pegaptanib, 74 bevacizumab, 167 ranibizumab) were reviewed. All injections were performed in an office-based setting. Povidone–iodine, topical antibiotics, and eye speculum were used as part of the pre injection procedure. Vision and intraocular pressure were evaluated immediately following each injection. Incidence of post injection complications, including but not limited to endophthalmitis, retinal detachment, traumatic cataract, and vitreous hemorrhage. There were no cases of endophthalmitis, toxic reactions, traumatic cataracts, retinal detachment, or vitreous hemorrhage. There was one case each of lid swelling, transient floaters, retinal pigment epithelial tear, corneal edema, and corneal abrasion. There were five cases of transient no light perception following pegaptanib injections. The incidence of serious complications was very low for the intravitreal injections given. A surgeon’s initial intravitreal injections may be performed with a very high degree of safety using this protocol.